+

WO2003048775A3 - Peptide und verfahren zum nachweis von morbus alzheimer und zur unterscheidung von morbus alzheimer gegenüber anderen demenziellen erkrankungen - Google Patents

Peptide und verfahren zum nachweis von morbus alzheimer und zur unterscheidung von morbus alzheimer gegenüber anderen demenziellen erkrankungen Download PDF

Info

Publication number
WO2003048775A3
WO2003048775A3 PCT/DE2002/004360 DE0204360W WO03048775A3 WO 2003048775 A3 WO2003048775 A3 WO 2003048775A3 DE 0204360 W DE0204360 W DE 0204360W WO 03048775 A3 WO03048775 A3 WO 03048775A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
disease
alzheimer
concentration
specific
Prior art date
Application number
PCT/DE2002/004360
Other languages
English (en)
French (fr)
Other versions
WO2003048775A2 (de
Inventor
Norbert Lamping
Hans-Dieter Zucht
Hartmut Selle
Michael Juergens
Gabriele Heine
Ruediger Hess
Original Assignee
Biovision Ag
Norbert Lamping
Hans-Dieter Zucht
Hartmut Selle
Michael Juergens
Gabriele Heine
Ruediger Hess
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovision Ag, Norbert Lamping, Hans-Dieter Zucht, Hartmut Selle, Michael Juergens, Gabriele Heine, Ruediger Hess filed Critical Biovision Ag
Priority to US10/497,073 priority Critical patent/US20050048584A1/en
Priority to CA002467073A priority patent/CA2467073A1/en
Priority to AU2002363825A priority patent/AU2002363825A1/en
Priority to JP2003549919A priority patent/JP2005511063A/ja
Priority to DE10295664T priority patent/DE10295664D2/de
Priority to EP02798252A priority patent/EP1451590A2/de
Publication of WO2003048775A2 publication Critical patent/WO2003048775A2/de
Publication of WO2003048775A3 publication Critical patent/WO2003048775A3/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Die vorliegende Erfindung betrifft definierte Peptide und deren quantitative Bestimmung in Körperflüssigkeiten von Patienten, die an Morbus Alzheimer leiden, relativ zu deren Konzentration in einer Kontrollgruppe von Patienten, die gesund sind oder an anderen demenziellen Erkrankungen leiden. Die erfindungsgemäßen Peptide entstammen aus dem C3f-Fragment des Proteinvorläufers Complement C3 mit dem korrespondierenden Gen und sind in spezifischer Art und Weise prozessiert und ggf. posttranslational oder chemisch modifiziert. Sie sind in einer für jedes Peptid spezifischen Weise in ihren Konzentrationen in Patienten relativ zur Kontrollgruppe verändert. Eine spezifische und signifikante Veränderung der Konzentrationen dieser Peptide relativ zu ihrer Konzentration in gesunden Personen zeigt eine Erkrankungen durch Morbus Alzheimer an. Die Erfindung findet darüber hinaus Verwendung zur Verlaufskontrolle, sowie zur Entwicklung von Diagnostika und Therapeutika.
PCT/DE2002/004360 2001-11-28 2002-11-27 Peptide und verfahren zum nachweis von morbus alzheimer und zur unterscheidung von morbus alzheimer gegenüber anderen demenziellen erkrankungen WO2003048775A2 (de)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US10/497,073 US20050048584A1 (en) 2001-11-28 2002-11-27 Method for detecting alzheimer's disease and differentiating alzheimer's disease from other demential diseases associated peptides and use thereof
CA002467073A CA2467073A1 (en) 2001-11-28 2002-11-27 Peptides and method for detecting alzheimer's disease and differentiating alzheimer's disease from other demential diseases
AU2002363825A AU2002363825A1 (en) 2001-11-28 2002-11-27 Peptides and method for detecting alzheimer's disease and differentiating alzheimer's disease from other demential diseases
JP2003549919A JP2005511063A (ja) 2001-11-28 2002-11-27 アルツハイマー病を検出する方法およびアルツハイマー病と他の痴呆疾患とを区別する方法、関連のペプチドおよびその使用
DE10295664T DE10295664D2 (de) 2001-11-28 2002-11-27 Verfahren zum Nachweis von Morbus Alzheimer und zur Unterscheidung von Morbus Alzheimer gegenüber anderen demenziellen Erkrankungen, zugehörige Paptide und deren Verwendungen
EP02798252A EP1451590A2 (de) 2001-11-28 2002-11-27 Peptide und verfahren zum nachweis von morbus alzheimer und zur unterscheidung von morbus alzheimer gegenüber anderen demenziellen erkrankungen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10158180.7 2001-11-28
DE10158180A DE10158180A1 (de) 2001-11-28 2001-11-28 Verfahren zum Nachweis von Morbus Alzheimer und zur Unterscheidung von Morbus Alzheimer gegenüber anderen demenziellen Erkrankungen, zugehörige Peptide und deren Verwendung

Publications (2)

Publication Number Publication Date
WO2003048775A2 WO2003048775A2 (de) 2003-06-12
WO2003048775A3 true WO2003048775A3 (de) 2004-01-29

Family

ID=7707147

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2002/004360 WO2003048775A2 (de) 2001-11-28 2002-11-27 Peptide und verfahren zum nachweis von morbus alzheimer und zur unterscheidung von morbus alzheimer gegenüber anderen demenziellen erkrankungen

Country Status (7)

Country Link
US (1) US20050048584A1 (de)
EP (1) EP1451590A2 (de)
JP (1) JP2005511063A (de)
AU (1) AU2002363825A1 (de)
CA (1) CA2467073A1 (de)
DE (2) DE10158180A1 (de)
WO (1) WO2003048775A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7049397B2 (en) * 2001-04-30 2006-05-23 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1211 daltons
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
WO2005098446A2 (en) * 2004-03-31 2005-10-20 The Johns Hopkins University Biomarkers for ovarian cancer
GB0421639D0 (en) * 2004-09-29 2004-10-27 Proteome Sciences Plc Methods and compositions relating to alzheimer's disease
US8865763B2 (en) 2005-10-14 2014-10-21 Alltech, Inc. Methods and compositions for altering cell function
CN102764279B (zh) * 2005-10-14 2015-04-01 全面技术公司 改变细胞功能的方法和组合物
US8871715B2 (en) 2005-10-14 2014-10-28 Alltech, Inc. Use of selenium compounds, especially selenium yeasts for altering cognitive function
EP1954718B1 (de) 2005-11-30 2014-09-03 AbbVie Inc. Anti-a-globulomer-antikörper, antigen bindende gruppen davon, entsprechende hybridome, nukleinsäuren, vektoren, wirtszellen, verfahren zur herstellung dieser antikörper, zusammensetzungen, die diese antikörper enthalten, verwendungen dieser antikörper und verfahren zur verwendung dieser antikörper
KR20140087058A (ko) 2005-11-30 2014-07-08 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) * 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
EP2558494B1 (de) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta-bindende proteine
CA2808187A1 (en) 2010-08-14 2012-02-23 Abbvie Inc. Amyloid-beta binding proteins
JP5960717B2 (ja) 2010-12-16 2016-08-02 オーティズム バイオテック リミテッド 自閉症の診断、治療におけるバイオマーカーおよびその使用
JP6012923B2 (ja) 2010-12-22 2016-10-25 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
GB201310203D0 (en) * 2013-06-07 2013-07-24 Electrophoretics Ltd Materials and methods relating to Alzheimer's disease
GB2515334A (en) * 2013-06-20 2014-12-24 Neuro Bio Ltd Biomarkers for alzheimer's Disease
US20160018798A1 (en) * 2014-07-17 2016-01-21 Toyota Motor Engineering & Manufacturing North America, Inc. Home control system from a vehicle
CN111108377A (zh) * 2017-07-14 2020-05-05 株式会社Ｍｃｂｉ 疾病检测方法
JP7457300B2 (ja) * 2018-08-29 2024-03-28 国立大学法人 岡山大学 神経変性疾患の診断用ペプチドマーカー
CN114150057B (zh) * 2021-12-21 2024-04-26 贾龙飞 一种诊断阿尔茨海默病的外泌体蛋白及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002088711A2 (en) * 2001-04-30 2002-11-07 Syn.X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 2021 daltons
WO2002088174A2 (en) * 2001-04-30 2002-11-07 Syn.X Pharma, Inc. Biopolymer marker having a molecular weight of 1865 daltons
WO2002088729A2 (en) * 2001-04-30 2002-11-07 Syn.X Pharma, Inc. Biopolymer marker having a molecular weight of 1562 daltons

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020160420A1 (en) * 2001-04-30 2002-10-31 George Jackowski Process for diagnosis of physiological conditions by characterization of proteomic materials
US20030100016A1 (en) * 2001-11-23 2003-05-29 George Jackowski Complement C3 precursor biopolymer markers predictive of Alzheimers disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002088711A2 (en) * 2001-04-30 2002-11-07 Syn.X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 2021 daltons
WO2002088174A2 (en) * 2001-04-30 2002-11-07 Syn.X Pharma, Inc. Biopolymer marker having a molecular weight of 1865 daltons
WO2002088729A2 (en) * 2001-04-30 2002-11-07 Syn.X Pharma, Inc. Biopolymer marker having a molecular weight of 1562 daltons

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AKIYAMA HARUHIKO ET AL: "Inflammation and Alzheimer's disease", NEUROBIOLOGY OF AGING, TARRYTOWN, NY, US, vol. 21, no. 3, May 2000 (2000-05-01), pages 383 - 421, XP002244292, ISSN: 0197-4580 *
GANU V S ET AL: "FACTOR C3F IS A SPASMOGENIC FRAGMENT RELEASED FROM C3B BY FACTORS I AND H THE HEPTADECA-PEPTIDE C3F WAS SYNTHESIZED AND CHARACTERIZED", MOLECULAR IMMUNOLOGY, vol. 26, no. 10, 1989, pages 939 - 948, XP009019520, ISSN: 0161-5890 *
WYSS-CORAY TONY ET AL: "Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 99, no. 16, 6 August 2002 (2002-08-06), August 6, 2002, pages 10837 - 10842, XP002258596, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
JP2005511063A (ja) 2005-04-28
AU2002363825A1 (en) 2003-06-17
EP1451590A2 (de) 2004-09-01
DE10158180A1 (de) 2003-09-11
CA2467073A1 (en) 2003-06-12
WO2003048775A2 (de) 2003-06-12
AU2002363825A8 (en) 2003-06-17
US20050048584A1 (en) 2005-03-03
DE10295664D2 (de) 2004-10-14

Similar Documents

Publication Publication Date Title
WO2003048775A3 (de) Peptide und verfahren zum nachweis von morbus alzheimer und zur unterscheidung von morbus alzheimer gegenüber anderen demenziellen erkrankungen
WO2002082075A3 (de) Verfahren zum nachweis chronisch-demenzieller erkrankungen, zugehörige peptide und nachweisreagenzien
WO1998045322A3 (en) Diagnosis method and reagents
WO2002059604A3 (en) Diagnosis and treatment of multiple sclerosis
WO2002062851A8 (en) Conformationally abnormal forms of tau proteins and specific antibodies thereto
WO2002046222A3 (en) Compositions and methods for diagnosing alzheimer's disease
WO2001085256A3 (en) Critical illness neuropathy
EP2305286A3 (de) Behandlung von Alzheimerkrankheit
WO2003063893B1 (en) Fgfr agonists
WO2003102016A3 (en) Amyloid peptide inactivating enzyme to treat alzheimer's disease
WO2003040183A3 (en) Compounds for the diagnosis/prevention/treatment of alzheimer's disease
SG121733A1 (en) Nucleic acid molecules polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
MXPA05008704A (es) Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas.
WO2004050907A3 (en) Method for determing predisposition to manifestation of immune system related diseases
BR0314713A (pt) Processos e reagentes para o tratamento de doenças e distúrbios associados com nìveis aumentados de citocinas pró-inflamatórias
WO2002046767A3 (en) Diagnosis and treatment of alzheimer's disease
WO2002016636A3 (en) Diagnostic and therapeutic use of a caveolae-associated integral membrane protein for alzheimer's disease and related neurodegenerative disorders
DE60143608D1 (de) Neueskollagen-ähnliches protein clac, dessen vorläufer und dafür kodierende gene
WO2003003979A3 (en) Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
WO2004003563A3 (en) Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases
WO2005000891A3 (en) Thrombopoietin proteins with improved properties
WO2008037720A3 (en) Means and methods for diagnosing and/or treating a subject at risk of developing heart failure
AU2003224120A1 (en) Diagnostic and therapeutic use of ensadin-0477 gene and protein for neurodegenerative diseases
WO2003056341A3 (de) Verfahren zur diagnose von brustkrebserkrankungen, zugehörige peptide und deren verwendungen
WO2007013041A3 (en) Monitoring of cardiac natriuretic peptides during diagnosis, managment, and treatment of cardiac diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2467073

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003549919

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002798252

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002798252

Country of ref document: EP

REF Corresponds to

Ref document number: 10295664

Country of ref document: DE

Date of ref document: 20041014

Kind code of ref document: P

WWE Wipo information: entry into national phase

Ref document number: 10295664

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 10497073

Country of ref document: US

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载